At present, lung transplantation (LT) is the treatment of choice for most end-stage lung diseases. Unfortunately, the prognosis is still relatively poor mainly due to chronic lung allograft disease (CLAD). Moreover, no early accurate biomark-ers of graft rejection are known, thus we assessed CLAD lung microenvironment by profiling extracellular vesicles (EVs) from bronchoalveolar lavage (BAL) of LT patients.
The pro-inflammatory role of EVs in chronic lung rejection / S. Franzi, M. Storaci, A. Palleschi, M. Pitasi, V. Musso, L. Morlacchi, V. Rossrtti, F. Gentile, F. Blasi, M. Nosotti, S. Ferrero, V. Vaira. ((Intervento presentato al convegno ISEV (International Society for Extracellular Vesicles) Annual Meeting tenutosi a Seattle nel 2023.
The pro-inflammatory role of EVs in chronic lung rejection
M. Storaci;A. Palleschi;V. Musso;F. Blasi;M. Nosotti;S. Ferrero;V. Vaira
2023
Abstract
At present, lung transplantation (LT) is the treatment of choice for most end-stage lung diseases. Unfortunately, the prognosis is still relatively poor mainly due to chronic lung allograft disease (CLAD). Moreover, no early accurate biomark-ers of graft rejection are known, thus we assessed CLAD lung microenvironment by profiling extracellular vesicles (EVs) from bronchoalveolar lavage (BAL) of LT patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ISEV 2023.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.31 MB
Formato
Adobe PDF
|
1.31 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
